Sentry LLC’s Novartis NVS Stock Holding History

Sentry LLC’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$460K	Hold	3,010	–	–	0.15%	73
2025 Q4	$415K	Hold	3,010	–	–	0.11%	79
2025 Q3	$386K	Hold	3,010	–	–	0.1%	84
2025 Q2	$364K	Hold	3,010	–	–	0.07%	87
2025 Q1	$336K	Hold	3,010	–	–	0.07%	90
2024 Q4	$293K	Hold	3,010	–	–	0.06%	95
2024 Q3	$346K	Sell	3,010 -35	-1%	-$3.97K	0.07%	91
2024 Q2	$324K	Hold	3,045	–	–	0.06%	86
2024 Q1	$295K	Hold	3,045	–	–	0.06%	95
2023 Q4	$307K	Hold	3,045	–	–	0.07%	90
2023 Q3	$310K	Hold	3,045	–	–	0.07%	91
2023 Q2	$307K	Hold	3,045	–	–	0.07%	98
2023 Q1	$280K	Buy	+3,045	New	+$266K	0.07%	96

Other funds holding NVS

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sentry LLC's NVS Position: Q1 2026 in Review

Sentry LLC held its Novartis (NVS) position steady in Q1 2026 at 3,010 shares worth $460K. The position accounts for 0.15% of the portfolio, ranked #73.

Sentry LLC first reported a position in NVS in Q1 2023 and has held it in 13 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

Sentry LLC held 3,010 shares of Novartis worth $460K as of Q1 2026.
Sentry LLC left its Novartis share count unchanged in Q1 2026.
Novartis made up 0.15% of Sentry LLC's portfolio in Q1 2026, its #73 holding.
Sentry LLC first reported a position in Novartis in Q1 2023 and has held it in 13 quarters since.
1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Sentry LLC's 13F filing for Q1 2026, filed 23 Apr 2026.